[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.非酒精性脂肪性肝病防治指南(2018年更新版).实用肝脏病杂志, 2018, 21:177-186.
[2]中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南(2010年修订版).现代医药卫生,2011,27(5):641-644.
[3] Zhou F , Zhou J, Wang W,et al. Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018: A systematic review and Meta-analysis. Hepatology,2019, 70(4):1119-1133.
[4] Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology,2010 ,52(5):1836-1846.[5] Zhou J, Waskowicz LR, Lim A, et al. A liver-specific thyromimetic, VK2809, decreases hepatosteatosis in glycogen storage disease type Ia. Thyroid, 2019,29(8): 1158-1167.
[6] Loomba R, Kayali Z, Noureddin M, et al. GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease. Gastroenterology, 2018, 155(5):1463-1473,e6.
[7] Harrison SA, Rinella ME, Abdelmalek MF, et al. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet, 2018,391(10126):1174-1185.
[8] Connolly JJ, Ooka K, Lim JK. Future pharmacotherapy for non-alcoholic steatohepatitis (NASH): Review of phase 2 and 3 trials. J Clin Transl Hepatol,2018, 6(3):264-275.
[9] Kruger AJ, Fuchs BC, Masia R,et al. Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis. Hepatol Commun,2018,2(5):529-545.
[10] Jayakumar S, Middleton MS, Lawitz EJ,et al. Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. J Hepatol,2019,70(1):133-141.
[11] Younossi ZM, Stepanova M, Lawitz E,et al. Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. Liver Int,2018 ,38(10):1849-1859.
[12] Soto MPD, Lim JK. Evaluating the therapeutic potential of cenicriviroc in the treatment of nonalcoholic steatohepatitis with fibrosis: A brief report on emerging data. Hepat Med,2020,12: 115-123.
[13] US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment draft guidance for industry. https://www.fda.gov/media/119044/download.
[14] Perumpail BJ, Li AA, John N,et al. The role of vitamin E in the treatment of NAFLD.Diseases, 2018, 6(4): 86.
[15] Lai CL, Chien RN, Leung NWY, et al. One-year trial of lamivudine for chronic hepatitis B.N Eng J Med,1998,339:61-68.
[16] 姚光弼,王宝恩,崔振宇,等. 拉米夫定治疗慢性乙型肝炎病人的长期疗效.中华肝脏病杂志,1999,7(2):80-83.
[17] 国家食品药品监督管理总局. 非酒精性脂肪性肝炎治疗药物临床试验指导原则(试行)[EB/ OL]. 北京:国家食品药品监督管理总局, 2019 - 12 - 17 [ 2019 - 12 - 30 ]. http:/ /www. nmpa. gov. cn/ WS04/ CL2138/372284. html.
[18] Connolly JJ, Ooka K, Lim JK. Future pharmacotherapy for non-alcoholic steatohepatitis (NASH): Review of phase 2 and 3 trials. J Clin Transl Hepatol,2018, 6(3): 264-275. |
